Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Downgrades NexImmune to Market Perform

Raymond James Downgrades NexImmune to Market Perform

Raymond James analyst Steven Seedhouse downgrades NexImmune (NASDAQ:NEXI) from Outperform to Market Perform.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Raymond James analyst Steven Seedhouse downgrades NexImmune (NASDAQ:NEXI) from Outperform to Market Perform.

Warner Bros Upgraded By Analyst, ‘Skeletons’ In Closet Have Been Accounted For

By AJ Fabino

March 17, 4:41 PM

Analysts at Wolfe Research on Friday upgraded Warner Bros Discovery Inc (NASDAQ: WBD), saying after a tumultuous 2022 the “skeletons in Warner's closet have been accounted for,” indicating an upside from here.

WBD

Wells Fargo Maintains Overweight on WEX, Raises Price Target to $185

By Benzinga Newsdesk

October 28, 9:31 AM

Wells Fargo analyst Jeff Cantwell maintains WEX (NYSE:WEX) with a Overweight and raises the price target from $170 to $185.

WEX

Credit Suisse Maintains Outperform on Visa, Raises Price Target to $245

By Benzinga Newsdesk

October 26, 7:37 AM

Credit Suisse analyst Moshe Orenbuch maintains Visa (NYSE:V) with a Outperform and raises the price target from $235 to $245.

$1000 Invested In Pioneer Natural Resources 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

January 10, 5:33 PM

Pioneer Natural Resources (NYSE:PXD) has outperformed the market over the past 15 years by 4.82% on an annualized…

PXD

Raymond James Downgrades NexImmune to Market Perform

Related Posts

Warner Bros Upgraded By Analyst, ‘Skeletons’ In Closet Have Been Accounted For

Wells Fargo Maintains Overweight on WEX, Raises Price Target to $185

Credit Suisse Maintains Outperform on Visa, Raises Price Target to $245

$1000 Invested In Pioneer Natural Resources 15 Years Ago Would Be Worth This Much Today